JLE

Epileptic Disorders

MENU

Valproate-induced reversible sensorineural hearing loss: a case report with serial audiometry and pharmacokinetic modelling during a valproate rechallenge Volume 16, numéro 3, September 2014

  • [Armon et al., 1990] Armon C., Brown E., Carwile S., Miller P., Shin C. Sensorineural hearing loss: a reversible effect of valproic acid. Neurology. 1990;40:1896-1898.
  • [Bondareva et al., 2004] Bondareva I.B., Jelliffe R.W., Sokolov A.V., Tischenkova I.F. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J Clin Pharm Ther. 2004;29:105-120.
  • [Fujii et al., 2009] Fujii A., Yasui-Furukori N., Nakagami T. Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations. Drug Des Devel Ther. 2009;2:139-144.
  • [Gidal et al., 2005] Gidal B.E., Baltes E., Otoul C., Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 2005;64:1-11.
  • [Hori et al., 2003] Hori A., Kataoka S., Sakai K. Valproic acid-induced hearing loss and tinnitus. Intern Med. 2003;42:1153-1154.
  • [Incecik et al., 2007] Incecik F., Akoglu E., Sangun O., Melek I., Duman T. Effects of valproic acid on hearing in epileptic patients. Int J Pediatr Otorhinolaryngol. 2007;71:611-614.
  • [Jankovic and Milovanovic, 2007] Jankovic S.M., Milovanovic J.R. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol. 2007;29:673-679.
  • [Jankovic et al., 2010] Jankovic S.M., Milovanovic J.R., Jankovic S. Factors influencing valproate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther. 2010;48:767-775.
  • [Park et al., 2002] Park H.M., Kang S.S., Lee Y.B. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther. 2002;27:419-425.
  • [Puentes et al., 1999] Puentes E., Puzantian T., Lum B.L. Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. Ther Drug Monit. 1999;21:351-354.
  • [Vucicevic et al., 2009] Vucicevic K., Miljkovic B., Pokrajac M., Prostran M., Martinovic Z., Grabnar I. The influence of drug-drug interaction and patients’ characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci. 2009;38:512-518.
  • [Williams et al., 2012] Williams J.H., Jayaraman B., Swoboda K.J., Barrett J.S. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J Clin Pharmacol. 2012;52:1676-1688.
  • [Yukawa, 1995] Yukawa E. A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. J Pharm Pharmacol. 1995;47:1048-1052.
  • [Yukawa et al., 1997] Yukawa E., To H., Ohdo S., Higuchi S., Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol. 1997;37:1160-1167.